Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935004 | 0.91 | MC4R (0.48) | MC4RMC5RHDAC1HDAC2KDM1A | |
| SCHEMBL30388584 | 0.89 | KDM1A (0.50) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL13618963 | 0.88 | KDM1A (0.44) | MC4RMC5RHDAC1HDAC2KDM1A | |
| SCHEMBL10614795 | 0.88 | HDAC1 (0.48) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL10616742 | 0.87 | KDM1A (0.49) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL24943587 | 0.85 | HDAC1 (0.55) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL3269912 | 0.83 | GPBAR1 (0.48) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL30022211 | 0.83 | GPBAR1 (0.48) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL1038626 | 0.83 | HDAC1 (0.48) | HDAC1HDAC2KDM1AMAOAMAOB | |
| SCHEMBL13614140 | 0.83 | MAOA (0.46) | HDAC1HDAC2KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8753641-B2 | Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy | UNIVERSITY OF ZURICH (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20090280057-A1 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy | MALLINCKRODT INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7582295-B2 | Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy | UNIVERSITY OF ZURICH (CH) | 2009-09-01 | — | — | US | disclosed |
| WO-2008021745-A2 | HEPATITIS C VIRUS ENTRY INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-6399631-B1 | 3-AMIDO OR 3-SULFONAMIDO; EATING DISORDERS IN HUMANS, DOGS AND CATS | PFIZER INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280057-A1 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy | ERCC4, DDB1, XRCC6 | MC4R 4356/4885MC5R 4182/4885HDAC1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.